Tremeau Pharmaceuticals
Manufacturing · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
53 Main St Ste 202, Concord, Massachuset...Phone Number
(646) 599-8601Website
www.tremeau.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Tremeau Pharmaceuticals
Tremeau Pharmaceuticals is committed to developing non-opioid pain therapies for patients with high unmet medical needs. They focus on serving communities by addressing persistent pain issues faced by individuals. The company aims to partner with others who share their dedication to improving the lives of those in pain. Their innovative approach positions them as leaders in the field of pain management.Explore more
Popular SearchesTremeau PharmaceuticalsTremeau Pharmaceuticals IncSIC Code 28,283NAICS Code 32,325Show moreTremeau Pharmaceuticals Org Chart
MF
Director, Finance & Accounting
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Tremeau Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Tremeau Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Tremeau Pharmaceuticals recently announced quarterly report
Tremeau Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Tremeau Pharmaceuticals
Product Launch: Get notified when Tremeau Pharmaceuticals launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Tremeau Pharmaceuticals is spiking on competitors!
Click to see if Tremeau Pharmaceuticals had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Tremeau Pharmaceuticals has new funding data
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Company Profile Activity
Activity Insights
Tremeau Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Tremeau Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Tremeau Pharmaceuticals.
Tremeau Pharmaceuticals financials insights
Gather financial insights about Tremeau Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2018
Other Financing Round
$5.2M
Tremeau Pharmaceuticals Tech Stack
A closer look at the technologies used by Tremeau Pharmaceuticals
Tremeau Pharmaceuticals News & Media
Tremeau Pharmaceuticals ASH 2021 Presentations Highlight Unmet Need for Non-Opioid Pain Treatments for Patients with Bleeding Disorders
CONCORD, Mass.--(BUSINESS WIRE)--Tremeau Pharmaceuticals will present three abstracts highlighting the need for new non-opioid treatment options for bleeding disorder patients during the 63rd American Society of Hematology Annual Meeting and Exposition in Atlanta. The Massachusetts-based pharmaceutical company is focused on providing non-opioid pain treatments for well-defined patient populations with significant unmet needs. “People with bleeding disorders have been left behind by the currentTremeau Expands Pipeline with Novel Non-Opioid Compound for the Treatment of Acute Pain
CONCORD, Mass.--(BUSINESS WIRE)--Tremeau Pharmaceuticals today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No. 17/240,446. Once issued, the patent will provide composition of matter patent protection for Tremeau’s novel deuterium-enriched etoricoxib compound, TRM-362 (d3-etoricoxib), through at least April 2041. Etoricoxib is a highly selective cyclooxygenase-2 (COX-2) non-steroidal anti-inflammatory drug (NSAID) withTremeau Pharmaceuticals Will Advance Non-Opioid Pain Program with Investment from Gurnet Point Capital
CONCORD, Mass.--(BUSINESS WIRE)-- #biotech--Tremeau has received funding from Gurnet Point Capital for the clinical development of TRM-201 (rofecoxib) to treat hemophilic arthropathy (HA).
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Tremeau Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Tremeau Pharmaceuticals is committed to developing non-opioid pain therapies for patients with high unmet medical needs. They focus on serving communities by addressing persistent pain issues faced by individuals. The company aims to partner with others who share their dedication to improving the lives of those in pain. Their innovative approach po... Read More
